organization · Reporting owner
venBio Global Strategic GP II, L.P.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | 10% owner · See Remarks | July 21, 2020 | July 22, 2020 |
| IPI Legacy Liquidation CoIMPL · Entity 15659 | 10% owner | April 27, 2021 | April 29, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date July 21, 2020 · Filed July 22, 2020
Jointly reported with Adelman Robert J, venBio Global Strategic Fund, L.P., venBio Global Strategic GP, Ltd., venBio Global Strategic Fund II L.P., venBio Global Strategic GP, L.P., venBio Global Strategic GP II, Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,406 |
Reported balance
After 2020-07-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-07-21 · Conversion · Acquired 78,175 · Balance 96,406 F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F10: Includes 18,231 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F7: The shares are held by Robert Adelman directly. |
| Common StockSEC Table I · non-derivative | Direct | 99,406 |
Reported balance
After 2020-07-21 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2020-07-21 · Purchase · Acquired 3,000 · Balance 99,406 F7: The shares are held by Robert Adelman directly. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,969,789 |
Reported balance
After 2020-07-21 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-07-21 · Conversion · Acquired 3,100,020 · Balance 3,969,789 F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: Includes 869,618 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F1: The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,418,325 |
Reported balance
After 2020-07-21 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-07-21 · Conversion · Acquired 3,941,949 · Balance 4,418,325 F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F5: Includes 476,376 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,268,325 |
Reported balance
After 2020-07-21 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2020-07-21 · Purchase · Acquired 850,000 · Balance 5,268,325 F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-07-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-07-21 · Conversion · Disposed 78,175 · Balance 0 F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F7: The shares are held by Robert Adelman directly. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-07-21 · Conversion · Disposed 3,100,020 · Balance 0 F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1: The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-21 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-07-21 · Conversion · Disposed 2,398,588 · Balance 0 F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-07-21 · Conversion · Disposed 490,411 · Balance 0 F8: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-07-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-07-16 · Conversion · Disposed 1,052,950 · Balance 0 F9: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 461,811 |
Reported balance
Holding disclosure · report date 2020-07-21 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 461,811 F1: The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. F2: The shares are held by venBio SPV, LLC, which is wholly-owned by venBio Global Strategic Fund, L.P. Robert Adelman is a managing director of venBio SPV, LLC and disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
F2: The shares are held by venBio SPV, LLC, which is wholly-owned by venBio Global Strategic Fund, L.P. Robert Adelman is a managing director of venBio SPV, LLC and disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
F3: Includes 869,618 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.
F4: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F5: Includes 476,376 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.
F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
F7: The shares are held by Robert Adelman directly.
F8: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F9: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F10: Includes 18,231 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020.
IPI Legacy Liquidation Co
Report date April 27, 2021 · Filed April 29, 2021
Jointly reported with venBio Global Strategic Fund II L.P., venBio Global Strategic GP II, Ltd., GOODMAN COREY S, Adelman Robert J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,759,791 |
Last balance in matching sequence
After 2021-04-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2021-04-27 · Conversion · Acquired 2,309,791 · Balance 2,309,791 F1: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date. F2: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F3: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F4: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F5: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Row 2 · 2021-04-27 · Purchase · Acquired 450,000 · Balance 2,759,791 F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series D Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-04-27 · Conversion · Disposed 5,876,034 · Balance 0 F1: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series C-3 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-04-27 · Conversion · Disposed 8,201,930 · Balance 0 F2: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series C-2 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-04-27 · Conversion · Disposed 8,845,942 · Balance 0 F3: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| Series C-1 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-04-27 · Conversion · Disposed 13,233,885 · Balance 0 F4: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
| 5% Convertible Note due 2021SEC Table II · derivative / convertible security · Expires 2021-12-31 | Direct | 0 |
Reported balance
After 2021-04-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-04-27 · Conversion · Disposed Not disclosed · Balance 0 F5: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date.
F2: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
F3: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
F4: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date.
F5: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price).
F6: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date July 01, 2020 · Filed July 06, 2020
Jointly reported with venBio Global Strategic Fund II L.P., venBio Global Strategic GP II, Ltd., Adelman Robert J, GOODMAN COREY S
Section 16 reporting ended · disclosed 2020-01-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 3,033,552 |
Last balance in matching sequence
After 2020-07-06 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2020-07-01 · Sale · Disposed 108,064 · Balance 3,041,955 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $35.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Row 2 · 2020-07-02 · Sale · Disposed 3,800 · Balance 3,038,155 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Row 3 · 2020-07-06 · Sale · Disposed 4,603 · Balance 3,033,552 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.07, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $35.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.07, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
F4: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
Checkmate Pharmaceuticals, Inc.
Report date May 13, 2022 · Filed May 17, 2022
Jointly reported with venBio Global Strategic Fund II L.P., venBio Global Strategic GP II, Ltd., GOODMAN COREY S, Adelman Robert J
Section 16 reporting ended · disclosed 2022-05-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,155,930 |
Last balance in matching sequence
After 2022-05-16 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-05-13 · Sale · Disposed 35,850 · Balance 2,251,730 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Row 2 · 2022-05-16 · Sale · Disposed 95,800 · Balance 2,155,930 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.44 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.44 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2022 Filed May 17, 2022 17:12 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 95,800 | $10.45 | $1,001,100.42 |
DisclosureSEC source: 0001567619-22-011111 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155,930 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.44 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 13, 2022 Filed May 17, 2022 17:12 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 35,850 | $10.45 | $374,464.01 |
DisclosureSEC source: 0001567619-22-011111 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,251,730 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 12, 2022 Filed May 12, 2022 20:47 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 124,525 | $10.39 | $1,294,312.85 |
DisclosureSEC source: 0001567619-22-010353 · doc1.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,287,580 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.435, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 11, 2022 Filed May 12, 2022 20:47 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 17,700 | $10.38 | $183,641.04 |
DisclosureSEC source: 0001567619-22-010353 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,412,105 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.45, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 10, 2022 Filed May 12, 2022 20:47 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 18,676 | $10.38 | $193,869.95 |
DisclosureSEC source: 0001567619-22-010353 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,429,805 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 09, 2022 Filed May 9, 2022 18:58 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 17,600 | $10.37 | $182,582.40 |
DisclosureSEC source: 0001567619-22-009850 · doc1.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,448,481 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 06, 2022 Filed May 9, 2022 18:58 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 48,334 | $10.37 | $501,233.25 |
DisclosureSEC source: 0001567619-22-009850 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,466,081 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 05, 2022 Filed May 9, 2022 18:58 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 20,743 | $10.37 | $215,104.91 |
DisclosureSEC source: 0001567619-22-009850 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,514,415 F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 04, 2022 Filed May 4, 2022 19:30 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 37,500 | $10.37 | $388,923.75 |
DisclosureSEC source: 0001567619-22-009528 · doc1.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,535,158 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 03, 2022 Filed May 4, 2022 19:30 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 79,475 | $10.37 | $824,433.91 |
DisclosureSEC source: 0001567619-22-009528 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,572,658 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.38, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| May 02, 2022 Filed May 4, 2022 19:30 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 153,700 | $10.38 | $1,595,974.69 |
DisclosureSEC source: 0001567619-22-009528 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652,133 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 29, 2022 Filed Apr 29, 2022 17:50 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 69,230 | $10.38 | $718,662.78 |
DisclosureSEC source: 0001567619-22-009203 · doc1.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,805,833 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 17:50 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 73,400 | $10.38 | $761,936.04 |
DisclosureSEC source: 0001567619-22-009203 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,875,063 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 17:50 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 47,396 | $10.38 | $491,979.96 |
DisclosureSEC source: 0001567619-22-009203 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,948,463 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 26, 2022 Filed Apr 26, 2022 18:40 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 64,683 | $10.38 | $671,558.31 |
DisclosureSEC source: 0001567619-22-008985 · doc1.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,995,859 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 25, 2022 Filed Apr 26, 2022 18:40 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 27,668 | $10.39 | $287,404.12 |
DisclosureSEC source: 0001567619-22-008985 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,060,542 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.43, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 22, 2022 Filed Apr 26, 2022 18:40 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 37,430 | $10.39 | $388,834.07 |
DisclosureSEC source: 0001567619-22-008985 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,088,210 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 21, 2022 Filed Apr 21, 2022 20:54 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 62,200 | $10.38 | $645,866.14 |
DisclosureSEC source: 0001567619-22-008823 · doc1.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125,640 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 20:54 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 85,611 | $10.39 | $889,387.00 |
DisclosureSEC source: 0001567619-22-008823 · doc1.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,187,840 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.38 to $10.40, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 19, 2022 Filed Apr 21, 2022 20:54 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | SaleCommon Stock | 399,923 | $10.42 | $4,165,238.04 |
DisclosureSEC source: 0001567619-22-008823 · doc1.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,273,451 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.37 to $10.44, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F4 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Conversion5% Convertible Note due 2021 · Derivative | Not disclosed | $0.00 | $1,359,799.28 |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · derivative · entry 7 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 101,457 shares Expires 2021-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F5 · derivative.exercise_date: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries C-1 Redeemable Convertible Preferred Stock · Derivative | 13,233,885 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · derivative · entry 6 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 808,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F4 · derivative.exercise_date: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F4 · derivative.expiration_date: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries C-2 Redeemable Convertible Preferred Stock · Derivative | 8,845,942 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · derivative · entry 5 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 540,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F3 · derivative.exercise_date: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F3 · derivative.expiration_date: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries C-3 Redeemable Convertible Preferred Stock · Derivative | 8,201,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · derivative · entry 4 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F2 · derivative.exercise_date: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F2 · derivative.expiration_date: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionSeries D Redeemable Convertible Preferred Stock · Derivative | 5,876,034 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · derivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 358,878 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date. F1 · derivative.exercise_date: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date. F1 · derivative.expiration_date: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date. F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | PurchaseCommon Stock | 450,000 | $15.00 | $6,750,000.00 |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,759,791 F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 18:44 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | ConversionCommon Stock | 2,309,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-21-000408 · form4.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,309,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of the issuer's Series D redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's initial public offering ("IPO"), and had no expiration date. F2 · price: These shares of the issuer's Series C-3 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F3 · price: These shares of the issuer's Series C-2 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F4 · price: These shares of the issuer's Series C-1 redeemable convertible preferred stock automatically converted on a 16.37332-for-one basis into the number of shares of the issuer's common stock shown in Column 7 immediately upon closing of the issuer's IPO, and had no expiration date. F5 · price: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest automatically converted into the number of shares of the issuer's common stock shown in Column 7 upon the closing of the issuer's IPO at $13.50 per share (90% of the IPO price). F6 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 19:11 UTC | IPI Legacy Liquidation Co IMPL · Entity 15659 | Other5% Convertible Note due 2021 · Derivative | Not disclosed | $0.00 | $1,359,799.28 |
DisclosureSEC source: 0000905148-21-000392 · form4.xml · derivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 101,457 shares Expires 2021-12-31 F1 · derivative.exercise_price: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the "IPO") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021. F1 · kind: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the "IPO") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021. F1 · derivative.exercise_date: This convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into shares of the issuer's common stock shown in column 7 upon the closing of the issuer's initial public offering (the "IPO") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021. F2 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 21:00 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | ConversionSeries C Preferred Stock · Derivative | 3,644,624 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-20-000880 · form4.xml · derivative · entry 5 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 487,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 21:00 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | ConversionSeries B Preferred Stock · Derivative | 8,753,350 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-20-000880 · form4.xml · derivative · entry 4 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,314,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.exercise_date: The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · derivative.expiration_date: The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 21:00 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | ConversionSeries A Preferred Stock · Derivative | 12,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-20-000880 · form4.xml · derivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,671,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 21:00 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | PurchaseCommon Stock | 200,000 | $15.00 | $3,000,000.00 |
DisclosureSEC source: 0000905148-20-000880 · form4.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,673,374 F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 21:00 UTC | Checkmate Pharmaceuticals, Inc. CMPI · Entity 126718 | ConversionCommon Stock | 3,473,374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000880 · form4.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · price: The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.direct: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries B Convertible Preferred Stock · Derivative | 490,411 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · derivative · entry 10 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 490,411 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 2,398,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · derivative · entry 9 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,398,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,100,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · derivative · entry 8 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 3,100,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · ownership.nature: The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 78,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · derivative · entry 7 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 78,175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · ownership.direct: The shares are held by Robert Adelman directly. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 3,000 | $19.00 | $57,000.00 |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · nonDerivative · entry 5 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,406 F7 · ownership.direct: The shares are held by Robert Adelman directly. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 850,000 | $19.00 | $16,150,000.00 |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · nonDerivative · entry 4 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,268,325 F6 · ownership.nature: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 3,941,949 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · nonDerivative · entry 3 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,418,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · balance_after: Includes 476,376 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F6 · ownership.nature: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 3,100,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · nonDerivative · entry 2 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,969,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · balance_after: Includes 869,618 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F1 · ownership.nature: The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Robert Adelman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 78,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · nonDerivative · entry 1 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F10 · balance_after: Includes 18,231 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F7 · ownership.direct: The shares are held by Robert Adelman directly. Read SEC document |
| July 16, 2020 Filed Jul 22, 2020 01:29 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,052,950 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-20-000827 · form4.xml · derivative · entry 11 Adelman Robert J · CIK 0001329161 · 10% owner · See Remarks venBio Global Strategic Fund, L.P. · CIK 0001504130 · 10% owner · See Remarks venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner · See Remarks venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner · See Remarks venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner · See Remarks venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner · See Remarks venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,052,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, LP, venBio Global Strategic GP II, Ltd, and Mr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Read SEC document |
| July 06, 2020 Filed Jul 6, 2020 19:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 4,603 | $33.83 | $155,721.33 |
DisclosureSEC source: 0000905148-20-000773 · form4.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,033,552 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.07, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 19:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,800 | $33.63 | $127,805.40 |
DisclosureSEC source: 0000905148-20-000773 · form4.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,038,155 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 19:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 108,064 | $34.45 | $3,723,010.12 |
DisclosureSEC source: 0000905148-20-000773 · form4.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,041,955 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $35.20, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
| March 06, 2020 Filed Mar 6, 2020 17:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,800 | $23.79 | $42,830.82 |
DisclosureSEC source: 0001012975-20-000291 · edgar.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,150,019 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.41 to $24.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
| March 05, 2020 Filed Mar 6, 2020 17:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 8,500 | $23.53 | $200,010.95 |
DisclosureSEC source: 0001012975-20-000291 · edgar.xml · nonDerivative · entry 2 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,151,819 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 17:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 35,650 | $23.81 | $848,765.90 |
DisclosureSEC source: 0001012975-20-000291 · edgar.xml · nonDerivative · entry 1 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,160,319 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.86 to $24.12, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 17:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 6,401 | $23.00 | $147,198.68 |
DisclosureSEC source: 0001012975-20-000275 · edgar.xml · nonDerivative · entry 3 venBio Global Strategic Fund II L.P. · CIK 0001634632 · 10% owner venBio Global Strategic GP II, L.P. · CIK 0001729409 · 10% owner venBio Global Strategic GP II, Ltd. · CIK 0001729408 · 10% owner Adelman Robert J · CIK 0001329161 · 10% owner GOODMAN COREY S · CIK 0001278411 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,195,969 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $23.49, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F4 · balance_after: The number of shares reported in Column 5 has been reduced by 10,000 to correct a clerical error in the Reporting Person's Form 4 filed on February 12, 2020 and February 27, 2020. F5 · ownership.nature: These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.